ENGN

enGene TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$3.50

Analysis reference price unavailable

Analysis 2026-08-05 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$1.80

Analysis reference price unavailable

Analysis 2026-08-05 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.90

Analysis reference price unavailable

Analysis 2026-08-05 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-05

AI commentary

News flow is event-driven and mixed, with clinical, regulatory, restructuring, and upcoming KOL-event headlines. The deterministic score is negative, while primary-company evidence supports only a conditional recovery case. Social context, options data, short interest, employee sentiment, and analyst-revision detail are unavailable; conviction should remain low.

RankAlpha Sentiment Codex - 2026-08-05

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-11eventVirtual NMIBC KOL eventHigh impact

enGene announced a virtual KOL event on emerging NMIBC market insights for August 11, 2026. The packet does not indicate that new clinical data or guidance will be provided.

2026-09-30eventLEGEND 12-month durability data and FDA engagementHigh impact

enGene is awaiting 12-month complete-response and durability data from the LEGEND pivotal cohort and expects to engage with the FDA in the second half of 2026 regarding a potential BLA filing for detalimogene [#SEC-8K-2026-06-15].

2026-12-31catalystPotential detalimogene BLA filing pathHigh impact

Management plans to initiate a BLA filing for detalimogene in the second half of 2026, subject to additional durability data and FDA interaction [#SEC-8K-2026-06-15] [#PR-EARNINGS-2026-06-15].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-05 • Updated nightlySource: Internal modelMethodology